Table 3.
Summary of Anti-RBD IgG concentration and nAb titers at day-0 and day-42 time points.
| Summary of Anti-RBD IgG concentration | |||||
|---|---|---|---|---|---|
| Day-0 Testing |
Day-42 testing |
||||
| Vaccine arm | GMC; EU/mL Number of subjects (N) |
95% CI | GMC, EU/mL Number of subjects (N) |
95% CI | Ratio of CORBEVAX™ to COVISHIELD™ |
| CORBEVAX™ | 1439 N = 304 |
1268 –1633 | 24478 N = 304 |
21075 –28431 | 1.51 |
| COVISHIELD™ | 1503 N = 307 |
1316–1716 | 16203 N = 307 |
14428–18196 | |
| Summary of nAb titers against Ancestral and Delta strains | |||||
| CORBEVAX™ -Ancestral | 85 N = 303 |
75–96 | 2123 N = 301 |
1801 –2514 | 1.15 |
| COVISHIELD™ -Ancestral | 75 N = 307 |
65–86 | 1833 N = 304 |
1632 – 2089 | |
| CORBEVAX™ -Delta | ND | ND | 874 N = 301 |
724–1055 | 1.56 |
| COVISHIELD™ -Delta | ND | ND | 562 N = 304 |
482–657 | |